Therapeutic Response

IDH1 p.R132S status confers therapeutic sensitivity to Ivosidenib in patients with Acute Myeloid Leukemia.

Statements

Source and description
Tibsovo (ivosidenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Tibsovo (ivosidenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.